Literature DB >> 25924471

[The idiosyncratic hepatotoxicity of Polygonum multiflorum based on endotoxin model].

Chun-yu Li, Xiao-fei Li, Can Tu, Na Li, Zhi-jie Ma, Jing-yao Pang, Ge-liu-chang Jia, He-rong Cui, Yun You, Hai-bo Song, Xiao-xi Du, Yan-ling Zhao, Jia-bo Wang, Xiao-he Xiao.   

Abstract

The liver injury induced by Polygonum multiflorum Thunb. (PM) was investigated based on idiosyncratic hepatotoxicity model co-treated with lipopolysaccharide (LPS) at a non-hepatotoxic dose. Sprague-Dawley (SD) rats were intragastrically administered with three doses (18.9, 37.8, 75.6 g crude drug per kg body weight) of 50% alcohol extracts of PM alone or co-treated with non-toxic dose of LPS (2.8 mg·kg(-1)) via tail vein injection. The plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were assayed and the isolated livers were evaluated for histopathological changes. The dose-toxicity relationships of single treatment of PM or co-treatment of LPS were investigated comparatively to elucidate the idiosyncratic hepatotoxicity of PM. The results showed that no significant alterations of plasma ALT and AST activities were observed in the groups of solo-administration of LPS (2.8 mg·kg(-1), i.v.) or different dosage (18.9, 37.8 and 75.6 g·kg(-1), i.g.) of PM, compared to normal control group (P > 0.05); while significant elevations were observed in the co-administration groups of PM and LPS. Treatment with LPS alone caused slight infiltration of inflammatory cells in portal area but no evident hepatocytes injury. Co-treatment with LPS and PM (75.6 g·kg(-1), i.g.) caused hepatocyte focal necrosis, loss of central vein intima and a large number of inflammatory cell infiltration in portal areas. When further reduce the dosage of PM, significant increases of plasma ALT and AST activities (P < 0.05) were still observed in co-administration groups of LPS and PM (1.08 or 2.16 g·kg(-1)), but not in LPS or PM solo-administration groups. Nevertheless, the co-treatment of low dosage of PM (0.54 g·kg(-1)) with LPS did not induce any alteration of plasma ALT and AST. In conclusion, intragastric administration with 75.6 g·kg(-1) of PM did not induce liver injury in normal rats model; while the 2 folds of clinical equivalent dose of PM (1.08 g·kg(-1)) could result in liver injury in the LPS-based idiosyncratic hepatotoxicity model, which could be used to evaluate the idiosyncratic hepatotoxicity of PM.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25924471

Source DB:  PubMed          Journal:  Yao Xue Xue Bao        ISSN: 0513-4870


  14 in total

1.  Idiosyncratic drug-induced liver injury linked to Polygonum multiflorum: A case study by pharmacognosy.

Authors:  Chun-Yu Li; Qin He; Dan Gao; Rui-Yu Li; Yun Zhu; Hui-Fang Li; Wu-Wen Feng; Mei-Hua Yang; Xiao-He Xiao; Jia-Bo Wang
Journal:  Chin J Integr Med       Date:  2017-05-18       Impact factor: 1.978

2.  Screening for main components associated with the idiosyncratic hepatotoxicity of a tonic herb, Polygonum multiflorum.

Authors:  Chunyu Li; Ming Niu; Zhaofang Bai; Congen Zhang; Yanling Zhao; Ruiyu Li; Can Tu; Huifang Li; Jing Jing; Yakun Meng; Zhijie Ma; Wuwen Feng; Jinfa Tang; Yun Zhu; Jinjie Li; Xiaoya Shang; Zhengsheng Zou; Xiaohe Xiao; Jiabo Wang
Journal:  Front Med       Date:  2017-03-17       Impact factor: 4.592

3.  Cis-stilbene glucoside in Polygonum multiflorum induces immunological idiosyncratic hepatotoxicity in LPS-treated rats by suppressing PPAR-γ.

Authors:  Ya-Kun Meng; Chun-Yu Li; Rui-Yu Li; Lan-Zhi He; He-Rong Cui; Ping Yin; Cong-En Zhang; Peng-Yan Li; Xiu-Xiu Sang; Ya Wang; Ming Niu; Ya-Ming Zhang; Yu-Ming Guo; Rong Sun; Jia-Bo Wang; Zhao-Fang Bai; Xiao-He Xiao
Journal:  Acta Pharmacol Sin       Date:  2017-06-26       Impact factor: 6.150

4.  Poria Attenuates Idiosyncratic Liver Injury Induced by Polygoni Multiflori Radix Praeparata.

Authors:  Dan Gao; Jing-Yao Pang; Cong-En Zhang; Chun-Yu Li; Can Tu; Hai-Zhu Zhang; Ming Niu; Yin Xiong; Xiao-He Xiao; Kui-Jun Zhao; Wei-Wei Gao; Jia-Bo Wang
Journal:  Front Pharmacol       Date:  2016-10-18       Impact factor: 5.810

5.  Metabolomic Study on Idiosyncratic Liver Injury Induced by Different Extracts of Polygonum multiflorum in Rats Integrated with Pattern Recognition and Enriched Pathways Analysis.

Authors:  Chun-Yu Li; Can Tu; Dan Gao; Rui-Lin Wang; Hai-Zhu Zhang; Ming Niu; Rui-Yu Li; Cong-En Zhang; Rui-Sheng Li; Xiao-He Xiao; Mei-Hua Yang; Jia-Bo Wang
Journal:  Front Pharmacol       Date:  2016-12-15       Impact factor: 5.810

6.  2,3,4',5-tetrahydroxystilbene-2-O-β-D-glucoside exacerbates acetaminophen-induced hepatotoxicity by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2.

Authors:  Shangfu Xu; Jie Liu; Jingshan Shi; Zhengtao Wang; Lili Ji
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

Review 7.  A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix.

Authors:  Mengting Zhou; Naihua Hu; Meichen Liu; Ying Deng; Linfeng He; Chaocheng Guo; Xingtao Zhao; Yunxia Li
Journal:  Biomed Res Int       Date:  2020-04-20       Impact factor: 3.411

Review 8.  Discrimination and Proper Use of Polygoni Multiflori Radix, Cynanchi Wilfordii Radix, and Cynanchi Auriculati Radix in Korea: A Descriptive Review.

Authors:  Beom-Joon Lee; Kyungjin Lee
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-11       Impact factor: 2.629

9.  Rapid Discovery of the Potential Toxic Compounds in Polygonum multiflorum by UHPLC/Q-Orbitrap-MS-Based Metabolomics and Correlation Analysis.

Authors:  Lifeng Han; Piao Wang; Yulan Wang; Qianyu Zhao; Fang Zheng; Zhiying Dou; Wenzhi Yang; Limin Hu; Caixiang Liu
Journal:  Front Pharmacol       Date:  2019-04-16       Impact factor: 5.810

10.  Screening for Susceptibility-Related Factors and Biomarkers of Xianling Gubao Capsule-Induced Liver Injury.

Authors:  Chun-Yu Li; Ming Niu; Ya-Lei Liu; Jin-Fa Tang; Wei Chen; Geng Qian; Ming-Yu Zhang; Ya-Fei Shi; Jun-Zhi Lin; Xing-Jie Li; Rui-Sheng Li; Xiao-He Xiao; Guo-Hui Li; Jia-Bo Wang
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.